Mersana Therapeutics Inc (MRSN)

02:00 AM

MRSN: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com

02:00 AM

11:44 AM

Mersana Therapeutics Inc. Stock Analysis and ForecastExtraordinary performance - Autocar Professional

11:44 AM

06:29 AM

Is Mersana Therapeutics Inc. a good long term investmentPowerful growth strategies - jammulinksnews.com

06:29 AM

04:36 AM

What analysts say about Mersana Therapeutics Inc. stockFree Predictions - Autocar Professional

04:36 AM

Jul 22, 2025

What drives Mersana Therapeutics Inc. stock priceHigh-octane financial growth - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Why Mersana Therapeutics Inc. stock attracts strong analyst attentionFree Group Entry - Newser

Jul 22, 2025

Jul 18, 2025

Mersana Therapeutics’ XMT-1660 Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 18, 2025

Jul 15, 2025

What makes Mersana Therapeutics Inc. stock price move sharplyTop Performing Low Risk Stocks - Newser

Jul 15, 2025

Jul 15, 2025

How Mersana Therapeutics Inc. stock performs during market volatilityConsistent Win Signals - Newser

Jul 15, 2025

Jul 11, 2025

Wealth Enhancement Advisory Services LLC Takes Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Jul 11, 2025

Jul 05, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Jul 05, 2025

Jul 03, 2025

Mersana Therapeutics Settles Debt with Oxford Finance - TipRanks

Jul 03, 2025

Jul 01, 2025

Biotech layoff tracker: 18 companies cut 1,300 jobs in Q2 2025 - The Business Journals

Jul 01, 2025

Jun 27, 2025

Mersana Therapeutics (MRSN) Plunges 5.23% Amid Drug Trial Data - AInvest

Jun 27, 2025

Jun 15, 2025

94,531 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Purchased by Pallas Capital Advisors LLC - Defense World

Jun 15, 2025

Jun 13, 2025

Mersana Therapeutics Approves Key Proposals at Annual Meeting - TipRanks

Jun 13, 2025

Jun 11, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Surges 28% Yet Its Low P/S Is No Reason For Excitement - simplywall.st

Jun 11, 2025

Jun 11, 2025

Two Sigma Investments LP Has $302,000 Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Jun 11, 2025

Jun 10, 2025

Layoff Tracker: National Resilience Closes 60% of Its Manufacturing Footprint - BioSpace

Jun 10, 2025

Jun 10, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Rating of “Buy” by Brokerages - Defense World

Jun 10, 2025

Jun 07, 2025

LifeSci Capital Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $3 - 富途牛牛

Jun 07, 2025

Jun 06, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Acquired by Nuveen Asset Management LLC - Defense World

Jun 06, 2025

Jun 06, 2025

Bank of America Corp DE Sells 36,084 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Jun 06, 2025

Jun 06, 2025

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Short Interest Up 21.4% in May - Defense World

Jun 06, 2025

Jun 05, 2025

Millennium Management LLC Increases Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Jun 05, 2025

Jun 04, 2025

Mersana Therapeutics’ (MRSN) “Outperform” Rating Reaffirmed at William Blair - Defense World

Jun 04, 2025

Jun 03, 2025

Mersana reports promising Phase 1 ADC trial results By Investing.com - Investing.com South Africa

Jun 03, 2025

Jun 03, 2025

Mersana reports promising Phase 1 ADC trial results - Investing.com India

Jun 03, 2025

Jun 03, 2025

Mersana Therapeutics Reports Additional Positive Interim Phase 1 - GuruFocus

Jun 03, 2025

Jun 02, 2025

Mersana Therapeutics (MRSN) Reveals Promising Phase 1 Trial Data - GuruFocus

Jun 02, 2025

Jun 02, 2025

Mersana Therapeutics (MRSN) Reveals Promising Phase 1 Trial Data for Cancer Treatment | MRSN Stock News - GuruFocus

Jun 02, 2025